{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T12:51:17Z","timestamp":1773838277385,"version":"3.50.1"},"reference-count":61,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2016,1,31]]},"DOI":"10.2217\/fon.15.294","type":"journal-article","created":{"date-parts":[[2015,12,3]],"date-time":"2015-12-03T09:12:53Z","timestamp":1449133973000},"page":"9-23","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["Pembrolizumab for the Treatment of Thoracic Malignancies: Current Landscape and Future Directions"],"prefix":"10.1080","volume":"12","author":[{"given":"Safiya","family":"Karim","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Princess Margaret Cancer Center\/University Health Network, 5-105 610 University Avenue, Toronto, ON, M5G 2M9, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natasha","family":"Leighl","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Princess Margaret Cancer Center\/University Health Network, 5-105 610 University Avenue, Toronto, ON, M5G 2M9, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2015,12,3]]},"reference":[{"key":"e_1_3_3_3_1","volume-title":"GLOBOCAN 2012, version 1.0. Cancer incidence and mortality worldwide: IARC Cancer Base No. 11","author":"Ferlay J","unstructured":"Ferlay J , SoerjomataramI, ErvikMet al. GLOBOCAN 2012, version 1.0. Cancer incidence and mortality worldwide: IARC Cancer Base No. 11 . International Agency for Research on Cancer. Lyon, France. http:\/\/globocan.iarc.fr."},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21254"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.9270"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.3747\/co.19.1114"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-199207000-00009"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-199502000-00010"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.07.035"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70510-2"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature12213"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa1348"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501824"},{"key":"e_1_3_3_15_1","unstructured":"US Food and Drug Administration Press Release. www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm465444.htm."},{"key":"e_1_3_3_16_1","unstructured":"US Food and Drug Administration website. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/125514lbl.pdf."},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1624"},{"key":"e_1_3_3_18_1","article-title":"MK-3475 (anti-PD-L1 monoclonal antibody) for non-small cell lung cancer: anti-tumor activity and association with tumor PD-L1 expression","volume":"74","author":"Ghandhi L","year":"2014","unstructured":"Ghandhi L , BalmanoukianA, HuiRet al. MK-3475 (anti-PD-L1 monoclonal antibody) for non-small cell lung cancer: anti-tumor activity and association with tumor PD-L1 expression. Cancer Res.74, Abstract CT105 (2014).","journal-title":"Cancer Res."},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501824"},{"issue":"5","key":"e_1_3_3_20_1","article-title":"Safety and clinical activity of MK-3475 in previously treated patients (pts) with non-small cell lung cancer (NSCLC)","volume":"32","author":"Garon E","year":"2014","unstructured":"Garon E , LeighlNB, RizviNAet al. Safety and clinical activity of MK-3475 in previously treated patients (pts) with non-small cell lung cancer (NSCLC). J. Clin. Oncol.32(Suppl. 5), Abstract 8020 (2014).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_3_21_1","unstructured":"Merck Keynote clinical trials website. http:\/\/keynoteclinicaltrials.com\/trials\/lung-cancer."},{"key":"e_1_3_3_22_1","unstructured":"Clinical trials database: NCT01840579. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01840579."},{"key":"e_1_3_3_23_1","unstructured":"Clinical trials database: NCT02039674. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02039674."},{"key":"e_1_3_3_24_1","article-title":"Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D","volume":"33","author":"Paitnak A","year":"2015","unstructured":"Paitnak A , SocinskiMA, GubensMAet al. Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D. J. Clin. Oncol.33(Suppl.), Abstract 8011 (2015).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_3_25_1","unstructured":"Clinical trials databse: NCT02007070. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02007070."},{"key":"e_1_3_3_26_1","volume-title":"16th Annual World Conference on Lung Cancer","author":"Weiss GJ","year":"2015","unstructured":"Weiss GJ , BarndtH, BlaydornL, SangalA, KhemkaV. Phase Ib\/II study of pembrolizumab plus chemotherapy in advanced cancer: results of lung cancer patients receiving \u2265 1 prior line of therapy. Presented at: 16th Annual World Conference on Lung Cancer. Denver, CO, USA, 6\u20139 September 2015."},{"key":"e_1_3_3_27_1","unstructured":"Clinical trials.database: NCT02085070. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02085070."},{"key":"e_1_3_3_28_1","volume-title":"16th Annual World Conference on Lung Cancer","author":"Goldberg SB","year":"2015","unstructured":"Goldberg SB , GettingerSN, MahajanAet al. A Phase II trial of pembrolizumab for untreated brain metastases from non-small cell lung cancer. Presented at: 16th Annual World Conference on Lung Cancer. Denver, CO, USA, 6\u20139 September 2015."},{"key":"e_1_3_3_29_1","article-title":"Pembrolizumab (MK-3475) in patients (pts) with extensive-stage small cell lung cancer (SCLC): preliminary safety and efficacy results from KEYNOTE-028","volume":"33","author":"Ott PA","year":"2015","unstructured":"Ott PA , FernandezMEE, HiretSet al. Pembrolizumab (MK-3475) in patients (pts) with extensive-stage small cell lung cancer (SCLC): preliminary safety and efficacy results from KEYNOTE-028. J. Clin. Oncol.33(Suppl.), Abstract 7502 (2015).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_3_30_1","unstructured":"American Association for Cancer Research Press Release\n. www.aacr.org\/Newsroom\/Pages\/News-Release-Detail.aspx?ItemID=696#.Vbafn-1Viko."},{"key":"e_1_3_3_31_1","unstructured":"Clinical trials.database: NCT02399371. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02399371."},{"key":"e_1_3_3_32_1","unstructured":"Clinical trials.database: NCT01905657. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01905657."},{"key":"e_1_3_3_33_1","unstructured":"Clinical trials.database: NCT02142738. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02142738."},{"key":"e_1_3_3_34_1","unstructured":"Clinical trials.database: NCT02220894. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02220894."},{"key":"e_1_3_3_35_1","unstructured":"Source: Bristol Myers Squibb. Press release: http:\/\/news.bms.com\/press-release\/fda-approves-opdivo-nivolumab-treatment-patients-previously-treated-metastatic-squamou."},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.3708"},{"issue":"5","key":"e_1_3_3_37_1","article-title":"First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: safety, efficacy, and correlation of outcomes with PD-L1 status","volume":"32","author":"Gettinger SN","year":"2014","unstructured":"Gettinger SN , ShepherdFA, AntoniaSAet al. First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: safety, efficacy, and correlation of outcomes with PD-L1 status. J. Clin. Oncol.32(Suppl. 5s), Abstract 8024 (2014).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_3_38_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.8072","article-title":"A Phase I study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus platinum-based doublet chemotherapy (PT-doublet) in chemotherapy-naive non-small cell lung cancer (NSCLC) patients (pts)","volume":"31","author":"Rizvi NA","year":"2013","unstructured":"Rizvi NA , AntoniaSJ, ChowLQMet al. A Phase I study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus platinum-based doublet chemotherapy (PT-doublet) in chemotherapy-naive non-small cell lung cancer (NSCLC) patients (pts). J. Clin. Oncol.31(Suppl.), Abstract 8072 (2013).","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"e_1_3_3_39_1","article-title":"Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC","volume":"32","author":"Rizvi NA","year":"2014","unstructured":"Rizvi NA , ChowmLQM, BorghaeiHet al. Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC. J. Clin. Oncol.32(Suppl. 5), Abstract 8022 (2014).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_3_40_1","unstructured":"Clinical trials.database: NCT02393625. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02393625."},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70054-9"},{"key":"e_1_3_3_42_1","article-title":"A Phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1 [PD-1]) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC)","volume":"33","author":"Spiegel DR","year":"2015","unstructured":"Spiegel DR , ReckampKL, RizviNAet al. A Phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1 [PD-1]) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC). J. Clin. Oncol.33(Suppl.), Abstract 8009 (2015).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_3_43_1","article-title":"Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC)","volume":"33","author":"Paz Azres L","year":"2015","unstructured":"Paz Azres L , HornL, BorghaeiHet al. Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC). J. Clin. Oncol.33(Suppl.), Abstract LBA109 (2015).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_3_44_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.7503","article-title":"Phase I\/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209\u2013032","volume":"33","author":"Antonia SJ","year":"2015","unstructured":"Antonia SJ , BendellJC, TaylorMRet al. Phase I\/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209\u2013032. J. Clin. Oncol.33(Suppl.), Abstract 7503 (2015).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-014-0305-5"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1177\/1758834014551747"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200694"},{"key":"e_1_3_3_48_1","unstructured":"Source: Roche. Press release: www.roche.com\/media\/store\/releases\/med-cor-2015\u20132007\u201313.htm."},{"key":"e_1_3_3_49_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.8029","article-title":"Clinical activity, safety and predictive biomarkers of the engineered antibody MPDL3280A (antiPDL1) in non-small cell lung cancer (NSCLC): update from a Phase Ia study","volume":"33","author":"Horn L","year":"2015","unstructured":"Horn L , SpiegelDR, GettingerSNet al. Clinical activity, safety and predictive biomarkers of the engineered antibody MPDL3280A (antiPDL1) in non-small cell lung cancer (NSCLC): update from a Phase Ia study. J. Clin. Oncol.33(Suppl.), Abstract 8029 (2015).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_3_50_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.8010","article-title":"Efficacy, safety and predictive biomarker results from a randomized Phase II study comparing MPDL3280A vs docetaxel in 2L\/3L NSCLC (POPLAR)","volume":"33","author":"Spira AI","year":"2015","unstructured":"Spira AI , ParkK, MazieresJet al. Efficacy, safety and predictive biomarker results from a randomized Phase II study comparing MPDL3280A vs docetaxel in 2L\/3L NSCLC (POPLAR). J. Clin. Oncol.33(Suppl.), Abstract 8010 (2015).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_3_51_1","unstructured":"Clinical trials database: NTC02008227. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02008227."},{"key":"e_1_3_3_52_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.2602","article-title":"Pharmacokinetics of MEDI4736, a fully human anti-PDL1 monoclonal antibody in patients with advanced solid tumors","volume":"32","author":"Fairman D","year":"2014","unstructured":"Fairman D , NarwalR, LiangMet al. Pharmacokinetics of MEDI4736, a fully human anti-PDL1 monoclonal antibody in patients with advanced solid tumors. J. Clin. Oncol.32(Suppl.), Abstract 2602 (2014).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_3_53_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.8032","article-title":"Safety and clinical activity of MEDI4736, an antiprogrammed cell death ligand 1 (PDL1) antibody, in patients with non-small cell lung cancer (NSCLC)","volume":"33","author":"Rizvi NA","year":"2015","unstructured":"Rizvi NA , BrahmerJR, OuSIet al. Safety and clinical activity of MEDI4736, an antiprogrammed cell death ligand 1 (PDL1) antibody, in patients with non-small cell lung cancer (NSCLC). J. Clin. Oncol.33(Suppl.), Abstract 8032 (2015).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_3_54_1","unstructured":"Clinical trials database: NCT02352948. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02352948."},{"key":"e_1_3_3_55_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.8034","article-title":"Avelumab (MSB0010718C), an anti-PD-L1 antibody, in advanced NSCLC patients: a Phase 1b, open-label expansion trial in patients progressing after platinum-based chemotherapy","volume":"33","author":"Gulley JL","year":"2015","unstructured":"Gulley JL , SpiegelD, KellyKet al. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in advanced NSCLC patients: a Phase 1b, open-label expansion trial in patients progressing after platinum-based chemotherapy. J. Clin. Oncol.33(Suppl.), Abstract 8034 (2015).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_3_56_1","unstructured":"Clinical trials database: NCT02395172. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02395172."},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.3708"},{"key":"e_1_3_3_59_1","volume-title":"16th Annual World Conference on Lung Cancer","author":"Sortino G","year":"2015","unstructured":"Sortino G . PD-L1 expression as a predictive biomarker in patients with non-small cell lung cancer: a pooled analysis. Presented at: 16th Annual World Conference on Lung Cancer. Denver, CO, USA, 6\u20139 September 2015."},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0130142"},{"key":"e_1_3_3_61_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.3001","article-title":"Biomarkers and associations with the clinical activity of PD-L1 blockade in a MPDL3280A study","volume":"31","author":"Powderly JD","year":"2013","unstructured":"Powderly JD , KoeppenH, HodiFSet al. Biomarkers and associations with the clinical activity of PD-L1 blockade in a MPDL3280A study. J. Clin. Oncol.31(Suppl.), Abstract e22118 (2013).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2015.01.020"},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature14011"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon.15.294","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:42:56Z","timestamp":1719124976000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon.15.294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,3]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1,31]]}},"alternative-id":["10.2217\/fon.15.294"],"URL":"https:\/\/doi.org\/10.2217\/fon.15.294","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2015-09-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-10-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-12-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}